Background: Kaposi sarcoma (KS) is the most common paediatric cancer in human immunodeficiency virus (HIV) endemic countries of sub-Saharan Africa, but there is little research on management and outcomes. Findings: Fifty-six children were included; 38 (68%) were male; and 48 (86%) were HIV positive, of whom 36 (77%) were on ART at diagnosis. Median age at diagnosis was 8 years (interquartile range [IQR] 3-12) and median follow-up was 16.9 months (IQR 3.4-36.4). Quality of life improved in 45 (80%) children; the median Lansky Score increased from 80% pre-treatment to 100% posttreatment. Eighteen (32%) children had complete response to treatment. At 12 months, overall survival was 71% (95% confidence interval [CI] 56-82) and event-free survival (event = death, loss to follow-up or relapse) was 50% (95% CI 36-63). At 1 year, the risk of loss to follow-up was 13.4%.
INTRODUCTION
Kaposi sarcoma (KS) is an aggressive, multifocal disease arising from vascular and lymphatic endothelial cells involving the skin and visceral 
METHODS

Site
The QECH is a 1,200 bedded government, tertiary hospital in Blantyre, Malawi. It is the teaching hospital for the medical school and receives referrals for the southern half of the country. The paediatric department admits 28,000 children annually and over 80,000 attend the emergency department and outpatients. The children's oncology unit has 23 beds and admits 300 patients annually. Children with KS are treated as outpatients unless they are systemically unwell.
Patient data
Data were collected on all children (<16 years) treated for KS with VBE between August 2012 and March 2015. Data included age at presentation, sex, HIV status; location, duration and number of KS cutaneous lesions; lymphadenopathy; oral cavity involvement and presence of pleural effusions, oedema, length of time on ART before the diagnosis of KS; and previous tuberculosis (TB) treatment. Baseline bloods included haematocrit (packed cell volume), white cell count, platelets; CD4 cell count and percentage if on ARTs for over a year; weight, sentinel node size and Lansky scores before and after treatment; and chemotherapy treatment, response and outcomes.
KS was diagnosed clinically, with biopsy confirmation if the diagnosis was in doubt. Biopsy confirmation was required in six cases.
HIV infection was confirmed using two rapid tests and eligibility for ART followed national guidelines. 16, 17 Quality of life was assessed using the Lansky score. 18 The chemotherapy regimen consisted of six courses of intravenous vincristine (1.5 mg/m 2 Day 1), bleomycin (15 IU/m 2 Day 1) and oral etoposide (100 mg/m 2 Days 1-3). The second course was given after one week and further courses were fortnightly.
Follow up
Children were reviewed 1 month after completing chemotherapy and 6 monthly thereafter. Treatment response was assessed by measurement of sentinel KS lesions before and after treatment. Complete response was defined as no clinical evidence of KS; partial response as a decrease of >50% in lesion size; stable disease as <50% reduction and poor response was no response or deterioration in the size of the KS lesions. Relapse was defined as apparent complete recovery followed by a return of the disease. Deaths on treatment were recorded.
Patients who did not complete treatment, failed to attend scheduled clinic visits or could not be traced were classified as defaulters after actively attempting to contact them. The time to progression of the disease was noted. (1) survival: only death was considered as an outcome -defaulters (abandonment) were censored at last follow-up appointment date, (2) retention: death and default were included together as an event (attrition) and (3) event-free survival: death, default and relapse were combined as an event.
Data analysis
Comparative raw data from the previous randomized controlled study of treatments with vincristine monotherapy or oral etoposide or combined vincristine and bleomycin were re-analysed in the same manner for comparison with our data, and with additional follow-up data compared with that presented in the previous publication.
As this was an audit of departmentally approved standard treatment no formal ethical approval was required.
RESULTS
Fifty-six children of whom 38 (68%) were males were enrolled. Median age at diagnosis was 8 years (interquartile range [IQR] 3-12). Median weight for age at enrolment was -2.29 (IQR -2.64 to 0.17); but is an unreliable measure of nutrition as many children had tumourrelated lymphoedema or missing data (see Table 1 Oedema n (%) 
F I G U R E 1 (A-C)
Survival, retention, and event-free survival for VBE combination therapy compared to separate E, V and VB therapies over 24 months lymphadenopathy (n = 52; 93%) and/or palatal lesions (n = 23; 41%) ( Table 1 ). The median Lansky score at baseline was 80% (IQR 50-90) and number of treatments given was 6 (IQR 3-6). Seventeen (30.4%) children received additional VBE treatments when they relapsed.
Number of treatments
Not all children survived to receive six courses of chemotherapy as many of them had advanced disease. Thirty-four (60.1%) children completed all six treatments.
HIV negative children
All eight (14%) HIV-negative children presented with generalized (n = 5) or localized (n = 3) lymphadenopathy. Six had associated oedema, three had palatal lesions and one had a pleural effusion. Skin lesions if present were few in number. These children were younger (mean age 6.9 (range 2-13 years)) than HIV-infected children (mean age 7.9 (range 1-15 years)). The ratio of males to females was 7:1 compared to 1.8:1 in HIV-infected children. Two of the eight children had a sibling who had also been treated for KS. Both were diagnosed by histology and presented with generalized lymphadenopathy. Two children died during treatment, one of the five who completed treatment absconded, three had complete responses, one had a partial response and one had stable disease.
Outcomes
In 18 (32%) children, there was complete response to treatment; partial response (>50% reduction in size of sentinel lesion) was seen in 12 (21%), three (5%) were stable (<50% reduction) and seven (12.5%) had no response or disease progression (Table 2 ).
In 45 (80%) children, the quality of life, using the Lansky score pre-and post-treatment, was higher after therapy, 10 (18%) were unchanged and 1 (2%) was deteriorated ( Table 2) .
At 12 months, overall survival was 71% (95% CI 56-82), retention (children remaining after death and default excluded) was 60%
(95% CI 45-71) and event-free survival (where event = death, default or relapse) was 50% (95% CI 36-63) (Figures 1a-1c) . At 24 months follow-up, overall survival was 59% (95% CI 44-72) ( Table 3 ).
The risks of death and default were 26.4% (95% CI 16-39) and 13.4% (95% CI 6-24) at 12 months and 36.1% (95% CI 24-49) and 21.1% (95% CI 11-33) at 24 months, respectively (Table 4) .
Multivariate analysis
Overall, only a large number of treatments were significantly associ- 
DISCUSSION
Studies have shown that a combination of ART and chemotherapy in HIV-KS leads to better outcomes than either treatment alone. 19, 20 Questions Table S1 ). Due to small numbers of children in both of these studies, we do not have sufficient power to detect a significant difference at this level.
Our study shows combination VBE therapy has improved complete response rates to treatment; 32% compared to 9% for oral etoposide, 7% for vincristine and 17% for vincristine/bleomycin. As ART therapy significantly affects outcomes in KS, and as there was a significant difference between the duration of ART prior to starting chemotherapy between the VBE cohort and the RCT population, this could be a significant confounder, as shown by loss of significance oyn multivariate analysis (Supplementary Table S2 ). However, due to small numbers of children, we did not have the power to detect a significant difference.
There was a higher proportion of children with an improved quality of life after chemotherapy in the VBE cohort (80% v 72% with oral etoposide, the next best performing therapy; Table 2 ) but this difference was not statistically significant (Supplementary Table S2 ).
It is important to consider default as well as death, as loss to followup can be missed deaths, and this was not accounted for in previous studies. The risk of default in the RCT was slightly lower at 9.8% (95% CI 2.5-23.1) in the oral etoposide group and 10.7% (95% CI 2.7-25) in the vincristine/ bleomycin group at 12 months. This compares to 13.4 % (95% CI 5.9-24.1) in our study at 12 months (Table 4) . However, overall retention rates (children remaining after excluding death and default) were higher in our study 43% (95% CI 29-55) at 24 months compared to the best-performing agent oral etoposide in the RCT 38%
(95% CI 18-57) ( Table 3) .
To separate the effects of chemotherapy from early mortality of very ill children who died of overwhelming disease, the children who completed the full course of treatments were analysed separately.
Their survival rates were 87% at 12 months and 75% at 24 months.
Increasing number of treatments was the biggest protective factor for death, attrition and any event (including relapse). This probably reflects that children with more advanced disease or lower CD4
counts at baseline were likely to die early regardless of treatment.
Even when the multivariate analysis was repeated without number TA B L E 3 Comparison of survival, retention (children remaining after death and loss to follow-up excluded) and event-free survival (event 10 A review of 70 children from South African hospitals reported 40% survival using single or multi-drug combinations of vincristine, doxorubicin and bleomycin in 52 children who were followed for an average of 16 months. 12 A study of 28 Mozambiquan children treated with paclitaxel and followed for 27 months reported 67% survival, but four children died of drug-related toxicity. 13 In 73 Ugandan children, 23 of the 24 who received chemotherapy with known outcomes had complete or partial remissions, 17 (70%) achieved complete remission and six achieved partial remission. No difference was observed in outcome when one or two drugs were given. However, there was significant LTFU, numbers were small and length of follow up was not documented. 11 It is difficult to compare survival outcomes in all these studies without knowing the stages of the HIV and KS infections and any co-infections.
All studies, including ours have shown that paediatric KS is more common in males than females and presents at a median age of 8 years.
Reassuringly more HIV-infected children in our study were already on ART than in previous studies.
There were fewer earlier deaths when using VBE combination 
Limitations
The main limitation to this study, and other paediatric KS studies, were the small numbers. This meant that we could not adequately power our statistical analysis of the various outcomes to detect significant difference in outcomes. Some children were lost to follow-up, although loss of 13.4% at 12 months and 21% at 24 months is comparable to other studies 11, 15 and survival estimates were adjusted for this loss.
CD4 counts were incomplete. Risk stratifying patients based on clinical characteristics as proposed by El-Mallawany et al. 8 may improve overall outcome by guiding treatment more appropriately.
We did not specifically record side effects of treatment or specifics around cause of death. We were aware of the concerns regarding bleomycin affecting lung interstitium. No clinically significant problems were seen with bleomycin in our patients and though we investigated chest problems as much as possible, it remains difficult to say if signs and symptoms were due to KS, bleomycin or HIV itself. It is also hard to say if some of the HIV-infected children developed KS immune reconstitution inflammatory syndrome after starting ART or it was a new infection. It would be an important consideration for future studies to record toxicity and toxic deaths related to chemotherapeutic agents.
The raw data from the previous RCT study were re-analysed for direct comparison with this study and therefore outcomes vary slightly from those previously reported.
CONCLUSION
This study shows that a combination regimen of VBE for treatment of childhood KS in resource-limited settings may improve survival, response to treatment and quality of life, but numbers were inadequate to confirm significant improvement. Larger clinical trials of this and other chemotherapy options in paediatric populations would validate treatment guidance.
